Hextend

Product manufactured by Hospira, Inc.

Application Nr Approved Date Route Status External Links
BN200952 None Intravenous None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

Indications And Usage Hextend (6% Hetastarch In Lactated Electrolyte Injection) Is Indicated In The Treatment Of Hypovolemia When Plasma Volume Expansion Is Desired. It Is Not A Substitute For Blood Or Plasma.

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Hetastarch

Comments